Introduction
Stroke, a common cerebrovascular disease, has high morbidity and mortality (Russo et al., 2011). The sudden blockade of a blood vessel by a thrombus or embolism results in ischemic stroke in more than 80% of patients (Donnan et al., 2008). Although the mechanisms underlying cerebral ischemia and reperfusion (I/R) injury are not fully clear, there is accumulating evidence that oxidative stress plays a major role in the pathogenic process (Allen and Bayraktutan, 2009). Excessive elevation of free radicals and reactive oxygen species (ROS) during cerebral I/R activates several signaling pathways and increases oxidative stress (Deb et al., 2010).
Acupuncture regulates body homeostasis and induces major physiological changes. It has been shown that electrical stimulation (electroacupuncture, EA) exhibits neuroprotective effects, and has been widely applied for the treatment of ischemic stroke in experimental animals and clinical practice (Wu et al., 2010; Wang et al., 2011). Although there are numerous mechanistic studies of EA focusing on neural pathways, regulation and neural responses (Tjen-A-Looi et al., 2006; Li et al., 2010), the mechanisms of neuroprotection remain unclear. A number of recent studies have shown that EA exerts anti-oxidative and anti-inflammatory effects that alleviate renal injury (Yu et al., 2015), lung injury (Yu et al., 2014) and Parkinson's disease (Lv et al., 2015). These effects of EA appear to be mediated via the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Several reports have also demonstrated that EA activates the PI3K/Akt and ERK1/2 signaling pathways or suppresses intracellular ERK and p38MAPK signaling to help repair spinal cord injury (Renfu et al., 2014) and alleviate neuropathic pain (Wang et al., 2015). Previous studies from our research group have shown that EA protects against oxidative stress (Li et al., 2005). However, it is not known whether the neuroprotective action of EA in cerebral I/R injury is mediated through the modulation of the ERK1/2 pathway. The aim of this study was to investigate the neuroprotective effect of EA in the rat model of middle cerebral artery occlusion (MCAO) and determine whether the therapeutic effect of EA is associated with the regulation of the ERK1/2 pathway.
Materials and Methods
Ethics statement
The animal studies were approved by the Animal Care and Use Committee of the Institute of Nanjing University of Chinese Medicine, and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Efforts were made to minimize suffering and the number of animals used in each experiment.
Animals
A total of 50 specific-pathogen-free adult male Sprague- Dawley rats, weighing 280–320 g, were provided by SLRC Laboratory Animals (Shanghai, China) (certification No. SCXK (Hu) 2007-0005) and housed under diurnal lighting conditions (12-hour light/dark cycle) for at least 1 week before surgery. Rats were randomly divided into the following five groups (n = 10 for each group): normal, sham-operation (sham), MCAO, MCAO + EA (EA), and MCAO + EA + PD98059 (EA plus PD98059) groups.
MCAO model establishment
Rats were allowed free access to food and water, but were fasted 12 hours before surgery. All animals were anesthetized by intraperitoneal injection of 10% chloral hydrate (Abbott, North Chicago, IL, USA). The MCAO model was performed as described previously, with minor modifications (Li and Cui, 2006). Briefly, the right common carotid artery, internal carotid artery and external carotid artery were exposed through a ventral midline neck incision. The internal carotid artery was then isolated and coagulated, and the proximal common carotid artery was ligated. A 4-0 monofilament nylon suture (Beijing Sunbio Biotech Co. Ltd., Beijing, China) with a rounded tip was inserted into the internal carotid artery from the common carotid artery through the external carotid artery stump and gently advanced 18 to 20 mm to occlude the middle cerebral artery. Core body temperature was maintained at 37.0 ± 0.5°C using a heating pad and heating lamp during the whole procedure. After 2 hours of MCAO, a neurological test was administered by an examiner blinded to the experimental groupings after MCAO using a modified scoring system based on that developed by Kuluz et al. (1993) as follows: 0, normal; 1, asymmetry of extension or abduction of the right upper extremity when lifted by the tail; 2, circling to the right during locomotion. A score of 2 was considered to indicate a successful model, and the suture was removed to restore blood flow (reperfusion). Rats in the sham group underwent identical surgery except that the suture was not inserted.
EA and PD98059 treatments
Stainless acupuncture needles, 0.3 mm in diameter (HuaTuo, Suzhou Medical Appliance Factory), were applied to both Baihui (DU20) (horizontal insertion of needle) and Dazhui (DU14) (oblique insertion of needle at an angle of 30°) acupoints in each rat (10 mm EA penetration depth, continuous wave with a frequency of 3 Hz, and a current intensity of 1–3 mA) ([Figure 1]), while the animals were undergoing reperfusion. The rats were acupunctured with an electrical needle stimulator (WQ1002K, Electro-Acupuncture Equipment Company, China) for 30 minutes.{Figure 1}
Rats in the EA plus PD98059 group received PD98059 administration as well as EA treatment. We first sterilized the skin over the lumbar spine, and then injected PD98059 (Sigma-Aldrich, St. Louis, MO, USA), an inhibitor of extracellular regulated kinase (ERK), into the intervertebral space (lumbar 4–5) using a microsyringe, at a dose of 2.78 mg/kg.
Neurological function assessment
24 hours after reperfusion, a neurological assessment of the rats in the five different groups was performed by a blinded investigator using the 18-point scoring system reported by Garcia et al. (1995). The system consisted of the following six tests: (1) spontaneous activity, (2) symmetry in the movement of four limbs, (3) forepaw outstretching, (4) climbing, (5) body proprioception, and (6) response to vibrissae touch. The score given to each rat at the completion of the evaluation was the summation of all six individual test scores, with a minimum neurologic score of 3 and a maximum score of 18.
Measurement of infarct volume
After neurological evaluation, rats were decapitated, and the brains were rapidly removed and frozen to preserve morphology during slicing. Infarct volumes were measured as described previously (Walcott et al., 2012). In brief, the brain was rapidly dissected and sectioned into five coronal blocks of an approximate thickness of 2 mm, and stained with 2% (w/v) 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich) for 30 minutes at 37°C, followed by overnight immersion in 4% (w/v) paraformaldehyde. The infarct area in each slice was demarcated and analyzed using Image J software (National Institutes of Health, Bethesda, MD, USA). The infarct volumes were calculated with the following formula: (total contralateral hemispheric volume−total ipsilateral hemispheric stained volume) / (total contralateral hemispheric volume) × 100%.
Histopathological examination
Hematoxylin-eosin (HE) staining was performed to show the morphological features of injured neurons in the cerebral cortex. 24 hours after MCAO, rats were sacrificed, and the brains were fixed by transcardial perfusion with saline solution, followed by perfusion and immersion in 4% paraformaldehyde. Brains were then dehydrated in a graded series of alcohols and embedded in paraffin. A series of 5-μm-thick sections were cut from the block. Finally, the sections were stained with HE reagents. The slices were observed and photographed with an Olympus BX50 microscope (Tokyo, Japan).
Transmission electron microscopy
Transmission electron microscopy was performed at 24 hours after MCAO. The cortex was cut into 1-mm3 cubes and fixed in 1% paraformaldehyde/2.5% glutaraldehyde for 24 hours. Samples were then fixed for 2 hours in 1% osmium tetroxide and dehydrated in a graded ethanol series and embedded in Araldite. The samples were cut into 50-nm-thick sections and stained with uranylacetate and lead citrate. The ultrastructure of pyramidal cells, astrocytes and blood-brain barrier (BBB) were observed with a Tecnai 12 transmission electron microscope (Philips, Eindhoven, Netherlands).
Quantitative real-time PCR
24 hours after MCAO, rats were sacrificed, and the ischemic cortex of the ipsilateral hemisphere was dissected. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. cDNA synthesis was performed using random hexamer primers and the TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Samples were subjected to real-time PCR analysis on a 7500 Sequence Detection System (Applied Biosystems) in accordance with the manufacturer's instructions. The primers and probes for rat Bax, Bcl-2, GCSh, GCSl, Nrf2 and GAPDH were designed with Primer Express 3.0 software (Applied Biosystems) using GenBank accession numbers. The primers are listed in [Table 1]. GAPDH was used as an internal control. mRNA quantities were calculated according to standard curves. Each sample was assayed in triplicate.{Table 1}
Measurement of glutathione reductase, glutathione and glutathione peroxidase
The blood samples were centrifuged at 3,000 × g, 4°C, for 15 minutes, and serum was extracted and stored at −80°C until analysis. The glutathione reductase (GR), glutathione (GSH) and glutathione peroxidase (GSH-Px) activities in the serum were measured using commercial kits (Jiancheng Bioengineering Institute, Nanjing, Jiangsu, China). The levels of GR, GSH and GSH-Px were expressed as units (U) /mg protein, mg/L and U, respectively.
Immunohistochemistry
Immunohistochemical analysis was performed to evaluate GCS and Nrf2 expression in brain cells 24 hours after MCAO. Cerebral cortical tissue samples were fixed in 4% paraformaldehyde overnight at room temperature. A series of 4−6-mm-thick tissue blocks were cut into five sections. The sections were deparaffinized and treated with 3% H2O2/methanol solution, followed by blocking with 5% goat serum in Tris-buffered saline. Then, the sections were incubated with rabbit anti-rat GCS monoclonal antibody (1:100; BA1627, Wuhan Boster Biotechnology Company, Wuhan, Hubei Province, China) or rabbit anti-rat Nrf2 monoclonal antibody(1:150; PB0327, Wuhan Boster Biotechnology Company), as the primary antibody, and then with horseradish peroxidase-conjugated goat anti-rabbit IgG, as the secondary antibody (1:100; BA1055, Wuhan Boster Biotechnology Company). After the sections were stained with DAB, images were acquired on a light microscope (Leica DM4000, Wetzlar, Germany) at 400× magnification. Morphometric analysis was performed in a blinded manner by two independent investigators. For each section, five visual fields were chosen at random for statistical analysis. Results were expressed as the mean optical density of the GCS or Nrf2 positive cells.
Statistical analysis
Data are expressed as the mean ± SEM and were analyzed with SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). Paired t-test was used to compare cerebral infarct volumes, while one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was used for multiple comparisons. P < 0.05 was considered statistically significant.
Results
EA alleviated neurological deficits after I/R in rats
To investigate whether EA improves neurological function in the rat model of MCAO, neurological testing was performed. After 2 hours of ischemia followed by 24 hours of reperfusion, rats subjected to MCAO exhibited significant motor deficits. Neurological function scores were significantly decreased in the MCAO group (P < 0.01; [Figure 2]A). Rats receiving EA showed significant improvements in neurological function compared with the MCAO group (P < 0.01; [Figure 2]A). To assess whether the ERK1/2 signaling pathway participates in the neuroprotective effect of EA, PD98059 (a specific ERK1/2 inhibitor) was used to block ERK1/2 signaling. As shown in [Figure 2]A, we found that the improvement in neurological function produced by EA was significantly abrogated in the EA plus PD98059 group, compared with the EA group (P < 0.01). This result suggests that EA attenuates neurological deficits via the ERK1/2 signaling pathway.{Figure 2}
EA reduced infarct volume in the ischemic brain
Infarct volume, a measure of stroke severity (Liu et al., 2009), was also assessed in the different groups. Extensive infarction was detected by TTC staining in the cerebral cortex in rats subjected to MCAO ([Figure 2]B). Rats treated with EA had lower infarct volumes than animals in the MCAO group (P < 0.001, [Figure 2]C), confirming the neuroprotective effect of EA against cerebral I/R injury.
EA attenuated cerebral damage after cerebral I/R injury
The neuroprotective effect of EA against cerebral I/R damage was supported by HE staining and transmission electron microscopy. HE staining showed no obvious pathological changes in rats in the sham group—pyramidal cells were tightly arranged, cellular morphology was normal, parenchymal integrity was normal, with light staining, and the nucleoli were clear in the cortex. In contrast, in the MCAO group, cortical pyramidal cells were sparse and showed a disordered arrangement. Furthermore, there was neuronal loss, and edema was present with karyopyknosis, with deep staining, and the nucleoli were not clearly visible. In the EA group, compared with the MCAO group, although pyramidal cells displayed a disordered arrangement, their number was normal, and edema was reduced in the cortex. In addition, there were many neurons with a normal morphology, and some cells also had a clearly visible nucleolus ([Figure 3]A).{Figure 3}
The ultrastructural changes in neurons and the BBB in the cerebral cortex observed by transmission electron microscopy are shown in [Figure 3]B, [Figure 3]C, [Figure 3]D. In the sham group, the pyramidal cells were characterized by around nucleus, evenly distributed chromatin, and a clear nucleolus and cytoplasm. The vascular endothelial cells had smooth and flat surfaces, and the endothelia, basement membranes and foot processes were in close contact. In contrast, pyramidal cells in the MCAO group displayed a shrunken nucleus, swollen organelles, chromatin condensation and marginalization, and the formation of apoptotic bodies. Vacuoles around small vessels were also observed. The glial cells around these vacuoles were not clearly detectable, and the inner surfaces of the blood vessels appeared rough. At high power, the endothelial cells appeared swollen, and the thickened basement membrane was not well organized. In the EA group, edema was reduced, and the organelles, cytoplasm and vasculature showed fewer pathological changes. Furthermore, the nuclei in neurons and glial cells appeared more normal. The vascular endothelial cells and the basement membrane exhibited smooth and intact surfaces with clear layers.
EA inhibited apoptosis following cerebral I/R
The proto-oncoproteins Bcl-2 and Bax are key regulators of the mitochondrial apoptotic pathway that is initiated by a variety of extracellular and intracellular stressors (Ferrer and Planas, 2003). To explore whether EA has anti-apoptotic effects, the mRNA expression of Bax and Bcl-2 in the ischemic cerebral cortex were investigated by real-time PCR after 24 hours of reperfusion. The MCAO group had significantly higher mRNA expression of Bax than the sham group (P < 0.05). Compared with the MCAO group, EA treatment significantly reduced Bax mRNA expression and increased Bcl-2 mRNA expression, and it increased the Bcl-2/Bax ratio in the ischemic cortex (P < 0.05; [Figure 4]).{Figure 4}
EA upregulated endogenous antioxidant systems following I/R
To further explore the mechanisms underlying the neuroprotective effect of EA, the levels of GR, GSH and GSH-Px in serum were measured to examine the oxidative response 24 hours after ischemia. GR, GSH and GSH-Px levels were significantly lower in the MCAO group compared with the sham group (P < 0.05). However, GSH, GSH-Px and GR levels were significantly higher in the EA group, compared with the MCAO group (P < 0.05). In addition, a substantial reduction in GR and GSH-Px activities was observed in the EA plus PD98059 group, compared with the EA group (P < 0.05, [Figure 5]).{Figure 5}
EA enhanced the expression levels of GCS and Nrf2 in the cortex of rats with cerebral ischemia and reperfusion injury
Nuclear factor-E2-related factor 2 (Nrf2) is a key transcription factor that regulates antioxidant genes in the adaptive response to oxidative stress (Ma et al., 2015). To identify whether Nrf2/GCS signaling is involved in the neuroprotective effect of EA, the ischemic cortex was analyzed by real-time PCR and immunohistochemistry. Real-time PCR analysis 24 hours following reperfusion showed that mRNA levels of GCSh and GCSl were significantly higher in rats in the EA group compared with rats in the MCAO group (P < 0.05). However, there was no significant difference in Nrf2 expression between the EA and MCAO groups. Moreover, in rats in the EA plus PD98059 group, there was a remarkable decrease in GCSh mRNA levels compared with the EA group (P < 0.05, [Figure 4]D, [Figure 4]E, [Figure 4]F).
Changes in expression of Nrf2 and GCS in the cortex were also analyzed by immunohistochemistry. The mean optical densities of Nrf2 and GCS-positive cells were higher in the EA group compared with the MCAO group (P < 0.01). The mean optical densities of Nrf2 and GCS-positive cells were lower in the EA plus PD98059 group compared with the EA group (P < 0.01, [Figure 6]).{Figure 6}
Discussion
In the current study, we found that EA protects the brain against I/R injury in rats subjected to MCAO. Notably, we found that the neuroprotective effect of EA is associated with the maintenance of the antioxidant system. Moreover, specific inhibition of the ERK1/2 pathway abolished the EA-induced increase in Nrf2 and GCS expression. Taken together, these findings suggest that EA attenuates cerebral I/R injury by activating the ERK1/2 signaling pathway and inducing Nrf2/GCS expression.
Apoptosis is thought to be pivotal in neuronal injury following cerebral I/R (Chen et al., 2014; Ji et al., 2014). Neuronal death or survival depends on the balance between pro-apoptotic (Bax) and anti-apoptotic (Bcl-2 and Bcl-xL) proteins during cerebral ischemia (Zhu et al., 1999; Sun et al., 2010). It is well known that the increase in brain damage is associated with increased apoptosis, as indicated by increased levels of Bax and decreased levels of Bcl-2. Accumulating evidence shows that the inhibition of apoptosis has a beneficial effect in acute ischemic stroke. For example, antisense knockdown of endogenous Bcl-2 exacerbates cerebral ischemic injury in rats and blocks the neuroprotection afforded by ischemic preconditioning (Chen et al., 2000; Shimizu et al., 2001). We observed a great number of apoptotic neurons in the brain of rats with MCAO 24 hours after reperfusion, and there was also a significant upregulation of Bax and a downregulation of Bcl-2. This is consistent with previous reports (Chen et al., 2015; Jie et al., 2015). Furthermore, we found that EA upregulated the anti-apoptotic protein Bcl-2 and downregulated the pro-apoptotic protein Bax, and reduced neuronal apoptosis. Further studies are required to clarify the mechanisms underlying the regulation of apoptosis by EA.
An imbalance between oxidative stress and antioxidant defense systems appears to play an important role in ischemic stroke injury (Love, 1999). GSH-Px, GR and superoxide dismutase (SOD) are the first line of defense against cerebral ischemic injury (Kontos, 2001). To clarify the effects of EA on oxidative stress induced by I/R injury, we measured the levels of GR, GSH-Px and GSH. EA restored GR, GSH and GSH-Px, suggesting that EA has an important anti-oxidative effect in I/R.
Nrf2, a key regulator of cell survival, has been implicated in the regulation of several key antioxidant enzymes such as γ-GCS, which plays an important role in antioxidant defense (Ma et al., 2015). We found that EA increases GSH content, and upregulated the expression of γ-GCS, the rate-limiting enzyme in GSH biosynthesis. Given that these genes are regulated by Nrf2, we infer that Nrf2 is a potential mediator of the neuroprotective effects of EA. Recent findings show that activation of Nrf2 significantly reduces the damage produced by ischemic stroke, suggesting that Nrf2 may represent a potential target for neuroprotection after cerebral ischemia (Zhao et al., 2011). In this study, EA significantly increased the expression of Nrf2 and GCS in the ischemic cortex 24 hours after MCAO, suggesting that the neuroprotective effect of EA might be associated with the upregulation of Nrf2 and GCS.
MAPK, including p38 MAPK, ERK1/2 and c-Jun N-terminal kinase (JNK) are considered to have critical roles in cerebral ischemia (Zhu et al., 2014). Studies have shown that p38 MAPK in the cortex and hippocampus exerted neuroprotective effects against ischemic brain injury (Zheng and Zuo, 2004; Blanquet et al., 2009; Zhao et al., 2013). Several reports have shown that p38 MAPK upregulated the expression of Bcl-2 and Bcl-xL in cerebral ischemic preconditioning models (Guan et al., 2014; Cheng et al., 2015). In addition, the PI3K/Akt and MAPK pathways activate the Nrf2 pathway (Jung and Kwak, 2010; Gong et al., 2015). Furthermore, the PI3K inhibitor LY294002 abolishes Nrf2 activation and heme oxygenase 1 (HO-1) induction (Qi et al., 2012). Previous studies have demonstrated that EA stimulation exerted neuroprotective effects against cerebral I/R injury by activating the ERK1/2 signaling pathway (Du et al., 2010; Xie et al., 2013; Huang et al., 2014). Taken together, these findings indicate that the ERK1/2 signaling pathway may be involved in the anti-apoptotic process and the activation of Nrf2. However, the mechanisms by which EA activates the Nrf2 pathway are unclear and require further investigation.
Studies have shown that EA stimulation, of different acupoints and at various frequencies, exerts neuroprotective effects against cerebral I/R injury in rats with MCAO. For example, EA stimulation at the Baihui acupoint (2/15 Hz) exerts anti-apoptotic and neuroprotective effects by increasing Bcl-2 expression and reducing glutamate toxicity (Zhu et al., 2013). EA stimulation (3 Hz) also improves behavioral performance by enhancing brain-derived neurotrophic factor production (Kim et al., 2012). Tian et al. (2015) demonstrated that EA stimulation at the Baihui, Mingmen (DU4) and Zusanli (ST36) acupoints (30/50 Hz) provided neuroprotection against brain edema in rats with MCAO. In this study, we chose the Baihui and Dazhui acupoints, based on our clinical experience (Li, 2007). EA stimulation at the Baihui acupoint improves nerve and periosteum function, enhances dredging, activates the Du meridian, and revives the brain. Moreover, EA stimulation at the Dazhui acupoint improves blood circulation to dissipate blood stasis, enhances brain function and alleviates brain disease. Our findings suggest that EA stimulation at Baihui and Dazhui acupoints, at a frequency of 3Hz, also exerts neuroprotective effects against cerebral I/R injury.
Our findings demonstrate that EA provides neuroprotection against cerebral I/R via activation of the ERK1/2 pathway. The potent efficacy of EA in protecting against focal cerebral I/R injury makes EA a promising therapeutic strategy for stroke. However, the role of ERK1/2/Nrf2 in the neuroprotective effects of EA and the mechanisms by which EA affects the expression of Nrf2 are unclear and require further study. Moreover, additional research is needed to elucidate whether other signaling pathways and factors contribute to the neuroprotective effects of EA. Nonetheless, our study suggests that the ERK1/2 pathway plays a major role in neuroprotection against cerebral I/R injury.[49]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2016. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Electroacupuncture (EA) has anti-oxidative and anti-inflammatory actions, but whether the neuroprotective effect of EA against cerebral ischemia-reperfusion (I/R) injury involves modulation of the extracellular regulated kinase 1/2 (ERK1/2) signaling pathway is unclear. Middle cerebral artery occlusion (MCAO) was performed in Sprague-Dawley rats for 2 hours followed by reperfusion for 24 hours. A 30-minute period of EA stimulation was applied to both Baihui (DU20) and Dazhui (DU14) acupoints in each rat (10 mm EA penetration depth, continuous wave with a frequency of 3 Hz, and a current intensity of 1–3 mA) when reperfusion was initiated. EA significantly reduced infarct volume, alleviated neuronal injury, and improved neurological function in rats with MCAO. Furthermore, high mRNA expression of Bax and low mRNA expression of Bcl-2 induced by MCAO was prevented by EA. EA substantially restored total glutathione reductase (GR), glutathione (GSH) and glutathione peroxidase (GSH-Px) levels. Additionally, Nrf2 and glutamylcysteine synthetase (GCS) expression levels were markedly increased by EA. Interestingly, the neuroprotective effects of EA were attenuated when ERK1/2 activity was blocked by PD98059 (a specific MEK inhibitor). Collectively, our findings indicate that activation of the ERK1/2 signaling pathway contributes to the neuroprotective effects of EA. Our study provides a better understanding of the regulatory mechanisms underlying the therapeutic effectiveness of EA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Second Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province
2 Department of Clinical Laboratory, Jiangsu Province Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province
3 Department of Clinical Laboratory, Jiangsu Province Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine; College of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province
4 College of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province





